Insider Transactions in Q4 2022 at Laboratory Corp Of America Holdings (LH)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 08
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
1,116
-14.3%
|
$258,912
$232.67 P/Share
|
|
Nov 07
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-5.49%
|
$208,302
$233.77 P/Share
|
|
Nov 07
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-10.28%
|
$208,302
$233.77 P/Share
|
|
Nov 05
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+10.98%
|
-
|
|
Nov 05
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+18.77%
|
-
|
|
Nov 01
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
892
-6.41%
|
$198,024
$222.56 P/Share
|
|
Nov 01
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,007
+12.6%
|
-
|
|
Nov 01
2022
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
893
-4.83%
|
$198,246
$222.56 P/Share
|
|
Nov 01
2022
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,007
+9.8%
|
-
|
|
Nov 01
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
5,348
-13.65%
|
$1,187,256
$222.56 P/Share
|
|
Nov 01
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
12,032
+23.49%
|
-
|